MX2021006435A - Composicion liquida estabilizadora de toxina botulinica. - Google Patents

Composicion liquida estabilizadora de toxina botulinica.

Info

Publication number
MX2021006435A
MX2021006435A MX2021006435A MX2021006435A MX2021006435A MX 2021006435 A MX2021006435 A MX 2021006435A MX 2021006435 A MX2021006435 A MX 2021006435A MX 2021006435 A MX2021006435 A MX 2021006435A MX 2021006435 A MX2021006435 A MX 2021006435A
Authority
MX
Mexico
Prior art keywords
botulinum toxin
liquid composition
stabilizing liquid
stability
present
Prior art date
Application number
MX2021006435A
Other languages
English (en)
Inventor
Yeong- Mok Kim
Wanseop Paul Kim
Gi- Sik PARK
Jae- Min Park
Ae- Yeon Lee
Original Assignee
Huons Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huons Biopharma Co Ltd filed Critical Huons Biopharma Co Ltd
Priority claimed from PCT/KR2019/016669 external-priority patent/WO2020111852A1/ko
Publication of MX2021006435A publication Critical patent/MX2021006435A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición líquida estabilizadora de toxina botulínica que tiene el efecto de mejorar la estabilidad de la toxina botulínica, un método para prepararla y una composición farmacéutica que contiene la composición líquida estabilizadora y que tiene una estabilidad mejorada de la toxina botulínica; según la presente invención, dado que la actividad de la toxina botulínica líquida se mantiene durante un tiempo prolongado incluso a temperatura ambiente, existen ventajas de una excelente estabilidad al almacenamiento y una estabilidad de conservación y una fácil administración.
MX2021006435A 2018-11-30 2019-11-29 Composicion liquida estabilizadora de toxina botulinica. MX2021006435A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180151983 2018-11-30
KR1020190101723A KR102259423B1 (ko) 2018-11-30 2019-08-20 보툴리눔 독소의 안정화 액상 조성물
PCT/KR2019/016669 WO2020111852A1 (ko) 2018-11-30 2019-11-29 보툴리눔 독소의 안정화 액상 조성물

Publications (1)

Publication Number Publication Date
MX2021006435A true MX2021006435A (es) 2021-07-02

Family

ID=71082708

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006435A MX2021006435A (es) 2018-11-30 2019-11-29 Composicion liquida estabilizadora de toxina botulinica.

Country Status (11)

Country Link
US (1) US20220118065A1 (es)
EP (1) EP3888633A4 (es)
JP (1) JP7244959B2 (es)
KR (1) KR102259423B1 (es)
CN (1) CN113164387A (es)
AU (1) AU2019388106B2 (es)
BR (1) BR112021010439A2 (es)
CA (1) CA3121465C (es)
MX (1) MX2021006435A (es)
PH (1) PH12021551234A1 (es)
SG (1) SG11202105592XA (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220088623A (ko) 2020-12-18 2022-06-28 주식회사 에이티지씨 보툴리눔 독소의 액상 제제를 장기 보관하기 위한 약제학적 조성물
KR102551301B1 (ko) * 2022-10-28 2023-07-03 주식회사 파마리서치바이오 보툴리눔 독소를 포함하는 안정한 액상 제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1253932B1 (en) 2000-02-08 2005-04-27 Allergan, Inc. Botulinum toxin pharmaceutical compositions
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8617568B2 (en) 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
AU2018200288A1 (en) * 2008-12-10 2018-02-01 Allergan, Inc. Clostridial toxin pharmaceutical compositions
KR20110106346A (ko) * 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
CA2831908C (en) * 2011-03-31 2018-11-13 Medy-Tox Inc. Lyophilized preparation of botulinum toxin
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2018038585A1 (ko) * 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
AU2017326253B2 (en) * 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Also Published As

Publication number Publication date
AU2019388106A1 (en) 2021-06-17
EP3888633A4 (en) 2022-10-05
CA3121465A1 (en) 2020-06-04
PH12021551234A1 (en) 2021-12-06
US20220118065A1 (en) 2022-04-21
AU2019388106B2 (en) 2023-04-27
CA3121465C (en) 2023-09-26
JP2022509150A (ja) 2022-01-20
CN113164387A (zh) 2021-07-23
SG11202105592XA (en) 2021-06-29
KR102259423B1 (ko) 2021-06-02
KR20200066152A (ko) 2020-06-09
JP7244959B2 (ja) 2023-03-23
EP3888633A1 (en) 2021-10-06
BR112021010439A2 (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
PH12021551234A1 (en) Botulinum toxin-stabilizing liquid composition
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
ZA202203515B (en) Substituted pyridopyrimidinonyl compounds useful as t cell activators
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
PH12019550084A1 (en) Oligosaccharides for flavour generation
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
MY179951A (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
EA201990091A1 (ru) Способ получения и очистки натриевой соли гиалуроновой кислоты
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EP4327880A3 (en) Solid state form of ribociclib succinate
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
PH12017502112B1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
BR112017006425B8 (pt) Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos
JO3592B1 (ar) شكل بلوري جديد لمشتق بنزيميدازول وطريقة تحضيره
MX2016005006A (es) Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
PH12017501832A1 (en) Stabilized pharmaceutical composition
MX367321B (es) Composición para el cuidado de la piel y métodos para la misma.
NZ764463A (en) Heterocyclic compound and application thereof in medicine
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MX2023000198A (es) Inhibidores de atr y usos de estos.
BR112017022656A2 (pt) conservação in vitro de células terapêuticas